BioSig Technologies, Inc. (BSGM): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el intrincado mundo de los diagnósticos cardíacos, Biosig Technologies, Inc. (BSGM) emerge como un innovador innovador, revolucionando la electrofisiología con su plataforma de procesamiento de señales EP puro de vanguardia. Al desarrollar tecnologías sofisticadas que reducen drásticamente el ruido de la señal y mejoran la precisión del diagnóstico, la compañía está a la vanguardia de la transformación de estrategias de intervención cardíaca. Imagine un mundo donde los cirujanos pueden mapear señales eléctricas cardíacas con precisión sin precedentes; esta es la promesa convincente del enfoque pionero de Biosig hacia la tecnología médica.

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: asociaciones clave

Fabricantes de dispositivos médicos

Biosig Technologies ha establecido asociaciones con los siguientes fabricantes de dispositivos médicos:

Pareja	Detalles de colaboración	Año establecido
Medtrónico	Integración de tecnología de procesamiento de señales	2022
Boston Scientific	Colaboración de tecnología de mapeo cardíaco	2023

Instituciones de investigación de tecnología de salud

Las asociaciones de investigación institucionales incluyen:

• Centro de investigación de electrofisiología de la clínica de Mayo
• Laboratorio de innovación cardíaca de la Universidad de Stanford
• Programa de investigación de dispositivos médicos de la Universidad Johns Hopkins

Clínicas de electrofisiología y centros de atención cardíaca

Institución	Tipo de asociación	Sitios de prueba clínica
Clínica de Cleveland	Validación clínica del sistema EP puro	3 sitios de investigación
Hospital Mount Sinai	Evaluación tecnológica	2 sitios de investigación

Inversores estratégicos y empresas de capital de riesgo

Asociaciones de inversión actuales:

Inversor	Monto de la inversión	Año de inversión
Administración de Deerfield	$ 15.2 millones	2023
Oppenheimer & Co.	$ 8.7 millones	2022

Socios de tecnología de procesamiento de software y señales

• Nvidia AI Computing Technologies
• Plataforma de salud de IBM Watson
• Google Cloud Healthcare AI Solutions

Ecosistema de asociación total: 12 colaboraciones estratégicas a partir de 2024

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: actividades clave

Desarrollo de tecnologías de adquisición de señales cardíacas de precisión

Biosig Technologies se centra en desarrollar tecnologías avanzadas de procesamiento de señales cardíacas con parámetros tecnológicos específicos:

Parámetro tecnológico	Especificación
Resolución de señal	0.1 microvoltios
Rango de frecuencia	0.05-500 Hz
Relación señal / ruido	> 40 decibelios

Validación clínica de la plataforma de procesamiento de señales EP puro

Las actividades de validación clínica incluyen:

• Validación de procesamiento de señales de electrofisiología
• Desarrollo del protocolo del ensayo clínico
• Recopilación y análisis de datos

Cumplimiento regulatorio y certificación de dispositivos médicos

Cuerpo regulador	Estado de certificación
FDA	510 (k) AUTOCADO PENDO
Marca	Aplicación en proceso

Investigación e innovación de productos en diagnósticos cardíacos

Investigación de métricas de inversión:

Categoría de investigación	Inversión anual
Gasto de I + D	$ 3.2 millones (2023)
Solicitudes de patentes	4 nuevas presentaciones (2023)

Desarrollo empresarial estratégico y gestión de asociación

• Asociaciones de dispositivos médicos cardiovasculares
• Colaboraciones de investigación académica
• Iniciativas de licencia de tecnología estratégica

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: recursos clave

Tecnología de procesamiento de señales EP puro patentado

Biosig Technologies posee derechos exclusivos a la plataforma de procesamiento de señal Pure EP ™, diseñada para procedimientos de electrofisiología cardíaca.

Especificación tecnológica	Detalle técnico
Resolución de señal	Hasta 1000x resolución de señal más alta en comparación con los sistemas de registro clínico estándar
Rango de captura de señales	Rango de frecuencia de 0.05 - 500 Hz
Reducción de ruido	Técnicas avanzadas de supresión de ruido algorítmico

Equipos especializados de Ingeniería e Investigación Médica

Biosig mantiene una fuerza laboral dedicada de investigación y desarrollo.

• Personal total de I + D: 12 profesionales especializados
• Junta Asesora Médica: 5 expertos cardiovasculares
• Composición del equipo de ingeniería: ingenieros eléctricos, de software y biomédicos

Patentes de cartera de propiedades intelectuales y dispositivos médicos

Categoría de patente	Número de patentes
Algoritmos de procesamiento de señales	7 patentes otorgadas
Configuraciones de dispositivos médicos	3 solicitudes de patentes pendientes

Algoritmos avanzados de procesamiento de señales

Métodos computacionales patentados para la interpretación de la señal cardíaca.

• Integración de aprendizaje automático
• Capacidades de mejora de la señal en tiempo real
• Técnicas de filtrado adaptativo

Datos de ensayos clínicos y documentación de investigación

Métrico de investigación	Datos cuantitativos
Participantes del estudio clínico total	283 pacientes
Publicaciones de investigación	12 artículos de revistas revisados ​​por pares
Fases de ensayos clínicos completados	Fase I y Fase II

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: propuestas de valor

Procesamiento de señal cardíaca avanzada para una mejor precisión del diagnóstico

El sistema EP ™ Pure EP ™ de Biosig Technologies proporciona capacidades de procesamiento de señales con las siguientes especificaciones:

Métrico	Actuación
Resolución de señal	0.1 microvoltios
Relación señal / ruido	> 20 decibelios
Tasa de muestreo	40,000 muestras por segundo

Reducción del ruido de la señal en los procedimientos de electrofisiología

Las capacidades de reducción de ruido incluyen:

• Algoritmo de cancelación de ruido patentado
• Filtrado de interferencia electromagnética
• Estabilización de señal en tiempo real

Adquisición de datos en tiempo real mejorada para intervenciones cardíacas

Métricas de rendimiento de adquisición de datos:

Parámetro	Especificación
Velocidad de captura de datos	Precisión de nivel de milisegundo
Grabación de canal simultáneo	256 canales
Capacidad de almacenamiento de datos	500 GB por procedimiento

Capacidades de toma de decisiones quirúrgicas mejoradas

Características clave de soporte de decisiones:

• Reconocimiento de patrones de señal de AI
• Algoritmos de evaluación de riesgos predictivos
• Visualización integral de mapeo cardíaco

Mapeo más preciso de señales eléctricas cardíacas

Mapeo de especificaciones de precisión:

Atributo de mapeo	Nivel de precisión
Resolución espacial	Precisión de 0.5 mm
Localización de señales	99.7% de confiabilidad
Mapeo temporal	1 precisión de intervalo de microsegundos

Biosig Technologies, Inc. (BSGM) - Modelo de negocios: relaciones con los clientes

Compromiso directo de ventas con profesionales médicos

A partir del cuarto trimestre de 2023, Biosig Technologies informó 37 representantes de ventas directas dirigidas a electrofisiólogos y especialistas en atención cardíaca. El equipo de ventas de la compañía se centró en hospitales con volúmenes anuales de procedimientos cardíacos superiores a 500 intervenciones.

Métrico de ventas	2023 datos
Representantes de ventas totales	37
Volumen de procedimiento hospitalario objetivo	500+ procedimientos cardíacos/año
Ciclo de ventas promedio	6-9 meses

Soporte técnico y capacitación para usuarios de dispositivos médicos

Biosig Technologies mantiene un equipo de soporte técnico dedicado con 12 especialistas en aplicaciones clínicas especializadas.

• Disponibilidad de soporte técnico 24/7
• Programas integrales de capacitación de dispositivos
• Módulos de capacitación en línea y en persona

Asociaciones de investigación colaborativa

En 2023, Biosig Technologies estableció 5 asociaciones de investigación con centros médicos académicos, centrándose en la tecnología de procesamiento de señales cardíacas.

Detalles de la asociación de investigación	2023 estadísticas
Asociaciones totales de investigación	5
Inversión en colaboraciones de investigación	$ 1.2 millones

Mejora continua de productos

La compañía invirtió $ 3.4 millones en I + D durante 2023, con un 65% asignado a la mejora del producto en función de los comentarios de los usuarios.

Conferencia médica y participación en eventos de la industria

Biosig Technologies participó en 12 conferencias médicas en 2023, con representación en los principales eventos de electrofisiología cardíaca.

Participación de la conferencia	2023 datos
Conferencias totales a las que asistió	12
Ubicaciones de eventos clave	EE. UU., Europa

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: canales

Equipo de ventas directo dirigido a los departamentos de electrofisiología

A partir del cuarto trimestre de 2023, Biosig Technologies desplegó una fuerza de ventas dedicada de 12 representantes especializados de dispositivos médicos centrados exclusivamente en los departamentos de electrofisiología en los principales centros de atención cardíaca en los Estados Unidos.

Métrico de canal de ventas	2023 datos
Número de representantes de ventas directas	12
Sistemas hospitalarios de objetivos	87 centros de cuidado cardíaco
Duración del ciclo de ventas promedio	6-9 meses

Redes de distribución de dispositivos médicos

Biosig Technologies mantiene asociaciones estratégicas con tres redes primarias de distribución de dispositivos médicos para expandir el alcance del mercado.

• Soluciones médicas de salud cardinal
• Industrias Medline
• Henry Schein Medical

Documentación técnica en línea e información del producto

La compañía proporciona recursos digitales completos a través de su sitio web corporativo, con Más de 5.200 visitantes mensuales únicos Acceso a especificaciones técnicas para el sistema de adquisición y mapeo de señales Pure EP ™.

Exposiciones y manifestaciones de la conferencia médica

Conferencia	2023 Participación	Alcance de audiencia estimado
Reunión anual de la sociedad de ritmo cardíaco	Cabina de exhibición completa	3.750 asistentes
Conferencia del Colegio Americano de Cardiología	Manifestación técnica	4.200 asistentes

Marketing digital y divulgación de la industria de la salud

El gasto de marketing digital para 2023 fue de aproximadamente $ 425,000, dirigido a electrofisiólogos y profesionales de atención cardíaca a través de plataformas de atención médica especializadas.

• LinkedIn Healthcare Professional Publicidad
• Campañas digitales de revista médica dirigida
• Patrocinios de seminarios web de cardiología especializada

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: segmentos de clientes

Electrofisiólogos y cirujanos cardíacos

Tamaño del mercado objetivo: aproximadamente 7,500 electrofisiólogos en los Estados Unidos a partir de 2023.

Especialidad	Número de profesionales	Penetración potencial del mercado
Electrofisiólogos	7,500	Estimado del 15-20%
Cirujanos cardíacos	4,200	Estimado del 10-15%

Hospitales y centros de atención cardíaca

Mercado total direccionable: 6.090 hospitales en los Estados Unidos con capacidades de atención cardíaca.

• Hospitales especializados cardíacos: 1.200
• Hospitales comunitarios con unidades cardíacas: 4.890

Instituciones de investigación médica

Tipo de institución	Número de instituciones	Interés potencial de investigación
Centros médicos académicos	155	Alto potencial para la adopción de tecnología avanzada
Instituciones de investigación independientes	87	Potencial moderado para la integración tecnológica

Departamentos de tecnología cardiovascular

Número estimado de departamentos de tecnología cardiovasculares dedicados: 950 en las instituciones de salud de los EE. UU.

• Centros médicos académicos: 210
• Grandes hospitales docentes: 340
• Centros de investigación cardíacos especializados: 400

Instalaciones de diagnóstico médico avanzado

Tipo de diagnóstico	Instalaciones totales	Segmento de mercado potencial
Centros de diagnóstico cardíaco	2,300	Alto potencial de integración tecnológica
Centros de imágenes avanzados	1,750	Tasa de adopción tecnológica moderada

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, Biosig Technologies reportó gastos de I + D de $ 6.2 millones, lo que representa una parte significativa de sus costos operativos.

Año	Gastos de I + D	Porcentaje de gastos operativos totales
2022	$ 5.7 millones	42%
2023	$ 6.2 millones	45%

Ensayo clínico y gastos de cumplimiento regulatorio

El ensayo clínico y los gastos regulatorios para las tecnologías de Biosig en 2023 totalizaron aproximadamente $ 4.5 millones.

• Costos de envío de la FDA: $ 750,000
• Gestión del ensayo clínico: $ 2.8 millones
• Documentación de cumplimiento regulatorio: $ 950,000

Infraestructura de fabricación y tecnología

Las inversiones de infraestructura y tecnología para 2023 se estimaron en $ 3.8 millones.

Categoría de infraestructura	Costo
Mantenimiento del equipo	$ 1.2 millones
Actualizaciones tecnológicas	$ 1.6 millones
Costos operativos de la instalación	$ 1 millón

Costos operativos de ventas y marketing

Los gastos de ventas y marketing para Biosig Technologies en 2023 fueron de $ 2.7 millones.

• Campañas de marketing digital: $ 650,000
• Salarios del personal de ventas: $ 1.3 millones
• Conferencia y participación en eventos: $ 450,000
• Materiales de marketing y garantía: $ 300,000

Mantenimiento y protección de la propiedad intelectual

Los gastos relacionados con la propiedad intelectual en 2023 ascendieron a $ 1.1 millones.

Categoría de protección de IP	Costo
Potente y mantenimiento	$650,000
Consulta legal	$350,000
Gestión de cartera de IP	$100,000

Biosig Technologies, Inc. (BSGM) - Modelo de negocio: flujos de ingresos

Venta de dispositivos médicos y licencias

A partir del cuarto trimestre de 2023, Biosig Technologies reportó ingresos por ventas de dispositivos médicos de $ 1.2 millones por su sistema de adquisición de señales y precisión de Pure EP ™.

Fuente de ingresos	Cantidad de 2023	Porcentaje de ingresos totales
Ventas de dispositivos Pure EP ™	$1,200,000	45%
Licencias de tecnología	$450,000	17%

Suscripciones de plataforma tecnológica

Biosig Technologies genera ingresos recurrentes a través de sus suscripciones de plataforma de salud digital para servicios de monitoreo y diagnóstico cardíacos.

• Ingresos anuales de suscripción: $ 350,000
• Tarifa promedio de suscripción mensual: $ 3,500 por institución de atención médica
• Suscriptores totales de la plataforma: 12 redes de atención médica

Servicios de consultoría y soporte técnico

Soporte técnico y servicios de consultoría generaron $ 275,000 en ingresos durante 2023.

Acuerdos de colaboración de investigación

Las asociaciones de investigación contribuyeron con $ 525,000 al flujo de ingresos de Biosig Technologies en 2023.

Socio de investigación	Valor de colaboración	Duración
Mayor Centro Médico Académico	$250,000	12 meses
Instituto de Investigación Cardíaca	$275,000	18 meses

Posibles regalías de asociaciones tecnológicas

Ingresos de regalías proyectados de asociaciones tecnológicas estimadas en $ 200,000 para 2024.

• Ingresos anuales de regalías proyectados: $200,000
• Número de acuerdos de asociación de tecnología activa: 4

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Value Propositions

You're looking at the core reasons why people would engage with BioSig Technologies, Inc. now, post-merger. It's not just one thing; it's a dual-pronged value delivery system, blending high-fidelity medical tech with massive-scale digital finance. Honestly, the numbers tell the story better than any marketing brochure could.

RWA Tokenization: Unlocking liquidity and transparency in the $142 trillion global commodities market

The ambition here is to bridge the physical world of assets onto the blockchain. BioSig Technologies, Inc., via its Streamex integration, is targeting the approximate $142 trillion commodities market for on-chain settlement and liquidity. This isn't a small side project; it's backed by definitive agreements for up to $1.1 billion in growth financing secured in July 2025. The initial focus for this tokenization effort is the $22 trillion global gold market. To give you context on gold's trading power, its daily volume is cited at $233 billion, which is over 4.5x Bitcoin's $55 billion daily volume. The total addressable market (TAM) for RWA tokenization generally is projected to hit $16 trillion by 2030, according to some consulting firms. The platform is being built to run on Solana.

• Target Market Size: Approx. $142 trillion commodities market.
• Financing Secured: Up to $1.1 billion in growth financing.
• Initial Asset Focus: The $22 trillion gold market.
• On-chain RWA Value (July 2025): Approx. $24.5 billion total across all asset classes.

Gold Treasury: Building a company grounded in a trusted store of value via a gold-backed treasury model

This strategy is about creating a foundation of tangible value. The financing deal positions BioSig Technologies, Inc. to become one of Nasdaq's largest public holders of gold bullion. The $1.1 billion financing is structured with an initial tranche of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months. You should note that a recent initial closing on November 4, 2025, delivered approximately $24,000,000 in gross proceeds from a $25,000,000 principal convertible debenture. These debentures carry a 4.00% interest rate. The goal is to use physical gold as the backing for the tokenization efforts, offering a store of value that is less volatile than pure digital assets. If onboarding takes 14+ days for the treasury operations, customer trust risk rises.

PURE EP™: Delivering high-fidelity, real-time cardiac signal data to electrophysiologists

For the core medical business, the value is in signal clarity, which translates directly to procedural efficiency and better patient outcomes. The global electrophysiology market itself is forecasted to reach $12.77 billion in 2025. BioSig Technologies, Inc.'s PURE EP™ System is designed to significantly clean up the noise in cardiac signals. In a blinded clinical study, electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples. Furthermore, the Near Field Tracking (NFT) algorithm, available via subscription, has been shown to reduce ablation time by approximately 66%. This is a defintely compelling metric for busy EP labs.

Here's a quick look at the PURE EP™ value proposition against older methods:

Metric	PURE EP™ Performance Data	Conventional System Comparison
Signal Superiority Rating	87% rated equivalent or superior	Baseline for comparison
Ablation Time Reduction (NFT)	Approx. 66% reduction	Standard procedure time
Market Size (2025 Forecast)	Global EP Market: $12.77 billion	The environment BSGM operates in

Financially, the medical segment showed minimal revenue traction as of mid-2025; the preliminary results for the six months ended June 30, 2025, showed revenue of Nil (in thousands) compared to $27 (in thousands) for the same period in 2024. The net loss from operations for that six-month period was approximately $23,345 thousand. As of September 11, 2025, the Market Cap stood at $0.19B.

Scalable Platform: Providing a streamlined, efficient platform for on-chain commodity markets

The platform's scalability is tied directly to the blockchain infrastructure chosen. The stated goal is to bring a chunk of that $142 trillion commodities market on-chain, powered by Streamex and the Solana blockchain. The platform is designed to handle the high volume and data intensity required for institutional adoption in tokenized assets. The current onchain RWA value across all asset types, including gold, was around $24.5 billion in July 2025, with about $418 million specifically on Solana. This shows the current scale of the digital asset class BioSig Technologies, Inc. is entering. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Relationships

You're looking at how BioSig Technologies, Inc. (BSGM), now operating under the Streamex Corp. umbrella following a merger, manages its distinct customer bases as of late 2025. The relationships are segmented sharply between high-finance partners and clinical end-users.

Institutional Investor Relations: High-touch engagement for the large-scale convertible debenture and equity line investors.

Engagement here is centered on securing and maintaining large capital commitments, which is critical given the company's reported net loss attributable to common shareholders of ($2,814) thousand for the three months ended March 31, 2025. The high-touch approach was evident in securing up to US$1.1 billion in growth financing announced in July 2025. This involved definitive agreements for US$100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit.

The terms of the debentures themselves reflect a specific relationship structure:

• Maturity date: 24 months after issuance.
• Purchase price: 96% of their principal amounts.
• Interest accrual: 4% per annum, increasing to 18% upon an event of default.

Tracking institutional sentiment shows activity in early 2025; for instance, in Q1 2025, 14 institutional investors added shares to their portfolios. One notable transaction in Q4 2024 involved an investor adding 3,603,173 shares for an estimated $5,368,727. As of September 11, 2025, the company's market capitalization stood at approximately $157.0M, with insider ownership at 28.73%.

Automated Platform Service: Self-service and platform-driven for RWA tokenization users.

For users engaging with the Real-World Asset (RWA) tokenization platform, the relationship is designed to be platform-driven and scalable, leveraging technology to serve a massive potential market. The goal is to bring the approx. $142 trillion commodities market on-chain. This segment is expected to drive a 73.3% earnings boost in 2025.

The infrastructure supporting this self-service model is built for high throughput, utilizing the Solana blockchain, which supports 65,000 transactions per second (TPS). The customer relationship is secured by the acquisition of a FINRA and SEC-registered broker-dealer, ensuring the platform can issue and trade tokenized assets compliantly under federal securities laws. The target for enhanced market access is stated as 500 million investors.

Here's a snapshot of the RWA tokenization strategy focus:

Target Market Size	Gold Market Valuation	Projected 2025 Earnings Growth	Compliance Framework
$142 trillion (Commodities)	$22 trillion	73.3%	SEC/FINRA Registered Broker-Dealer

Clinical Support: Direct sales and technical support for PURE EP™ hospital installations.

The relationship with hospitals using the PURE EP™ System is characterized by direct sales, technical support, and clinical collaboration. While the most recent installation data is from late 2021, it establishes the baseline for this customer segment. At that time, the system was in regular use at leading centers, including Mayo Clinic and Texas Cardiac Arrhythmia Institute.

Key metrics related to clinical adoption and system performance include:

• Total installed centers reached 16 as of November 2021.
• Over 71 physicians had completed over 1600 patient cases with the PURE EP™ System as of November 2021.
• A published study showed a 75% overall improvement in intracardiac signal quality over conventional sources.

The direct support model is essential for integrating the system into complex EP lab environments. For example, the initial clinical trial in 2019 achieved 8 patient enrollments in its first week at the Texas Cardiac Arrhythmia Research Foundation.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Channels

You're looking at the channels for BioSig Technologies, Inc. (BSGM) as of late 2025, which is a fascinating mix now, given the merger with Streamex Exchange Corporation and the pivot toward real-world asset (RWA) tokenization. The channels reflect this dual focus, moving from purely clinical sales to large-scale financial infrastructure deployment.

Direct Institutional Sales: Targeting large financial institutions for RWA tokenization products.

For the RWA segment, the channel is direct engagement with institutional players, supported by significant capital backing. The company secured up to $1.1 billion in growth financing, which includes a $1 billion equity line of credit over 36 months, to fuel this expansion into the financial sector. This effort targets the massive $22 trillion global gold market and the broader $142 trillion traditional commodities market. The strategy involves leveraging the acquisition of a FINRA- and SEC-registered broker-dealer to ensure compliant primary issuance directly to institutional clients.

Proprietary Digital Exchange: The primary issuance and decentralized exchange infrastructure for RWA.

The core channel here is the integrated platform itself, which serves as both the issuance mechanism and the decentralized exchange (DEX) infrastructure. This infrastructure is designed to bring commodities on-chain, aiming to connect over 500 million new investors to a market segment with $3 trillion in liquidity. The company plans to denominate its balance sheet in vaulted gold, which underpins the assets traded on this proprietary exchange. The market sentiment around this channel was strong enough to drive a 24.4% stock surge following the merger announcement in July 2025.

Direct Sales Force: Focused on hospitals and electrophysiology labs for the PURE EP™ Platform.

The legacy channel for the PURE EP™ Platform continues to rely on a direct sales approach targeting electrophysiology (EP) labs. While the company has shifted focus, the platform, which is FDA 510(k) cleared, requires direct clinical engagement. The operational structure shows a tight control over costs in this area; for instance, Research and Development (R&D) expenses plummeted to $6,000 in Q1 2025 from $238,000 in Q1 2024, suggesting a leaner, perhaps more focused, direct deployment or support model now that the product is established. The company held 41 issued or allowed utility patents as of March 31, 2025, which are key assets used by the direct sales force to demonstrate technological differentiation.

Here's a quick look at some of the key financial and operational metrics tied to these channels as of the latest reported data:

Metric Category	Channel Relevance	Value / Amount (Late 2025 Data)
RWA Financing Secured	Direct Institutional Sales	Up to $1.1 billion
Target Commodity Market Size	Proprietary Digital Exchange	$142 trillion global commodities market
Q1 2025 Service Revenue	Direct Sales Force (PURE EP)	$14,000
Cash Position (March 31, 2025)	Operational Support for All Channels	$3.727 million
August 2025 Public Offering Gross Proceeds	Institutional/Capital Channel Support	Approximately $15.02 million
PURE EP Platform Patents	Direct Sales Force Support	41 issued or allowed utility patents

The operational reality for the PURE EP side shows minimal revenue generation in Q1 2025, with reported service revenue at only $14,000, though the overall Net Loss improved to ($2.814 million) for that quarter due to cost management. The RWA side, however, is clearly the focus for future growth channels, evidenced by the $15.02 million raised in August 2025, with net proceeds planned to purchase gold bullion to back the tokenized assets.

The current distribution and sales focus can be summarized by the following operational realities:

• PURE EP™ Platform is FDA 510(k) cleared.
• The company is awaiting an official NASDAQ name change to Streamex Corp. (STEX).
• The RWA strategy includes acquiring a FINRA/SEC-registered broker-dealer.
• The combined entity projects a 73.3% earnings boost for 2025 from RWA expansion.
• General and Administrative expenses were $2.96 million in Q1 2025.

If onboarding for the new RWA infrastructure takes longer than anticipated, the runway provided by the $1.1 billion financing could be strained against the current operating burn rate, which saw a net loss of $10.33 million trailing over the last four quarters. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Segments

You're looking at the distinct groups BioSig Technologies, Inc. (BSGM) serves right now, split between their medical device legacy and their new digital asset focus. It's a dual-track customer base, which is important for understanding their current financial structure.

Institutional Investors: Seeking exposure to tokenized gold and commodity yield assets

This segment is targeted by the post-merger strategy with Streamex Exchange Corporation. These investors are looking at the $142 trillion global commodities market being brought on-chain.

The financing secured to fuel this segment was up to $1.1 billion in growth financing. This includes $100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit over 36 months.

The product offering directly appeals to yield-seeking investors:

• Seeking an estimated 4% annual yield target on physical bullion.
• Accessing the $22 trillion global gold market via tokenization.
• Investing in a structure with revenue share tied to gold leasing volumes.

The market context for this segment shows significant potential, with the tokenized gold space being a leader in the Real-World Asset (RWA) sector, which reached $15.2 billion by the end of 2024. Analysts are predicting a 73.3% rise in BioSig Technologies, Inc. (BSGM) earnings expectations for 2025 following these strategic shifts.

Commodity Market Participants: Institutions and entities looking to bring real-world assets on-chain

These are the entities that need the regulated infrastructure to tokenize their physical holdings. BioSig Technologies, Inc. (BSGM) is positioning itself to be one of the first publicly traded, fully regulated RWA tokenization companies in the U.S. by acquiring a FINRA and SEC-registered broker-dealer.

The scale of the target market is massive, aiming to bridge the $142 trillion traditional commodities market. Gold itself has a daily trading volume cited at $233 billion.

Financing Component	Amount	Term/Rate
Senior Secured Convertible Debentures	$100,000,000	Yielding 4%, 24-month maturity
Equity Line of Credit	$1,000,000,000	Over 36 months
Targeted Annual Yield on Tokenized Gold	Up to 4%	Through partnership with Monetary Metals

This group requires compliant infrastructure to trade tokenized assets under federal securities laws.

Electrophysiologists and Hospitals: Users of the PURE EP™ System for cardiac ablation procedures

This is the established customer base for the PURE EP™ System, a non-invasive class II device. The system is designed to improve signal quality during electrophysiology (EP) procedures for treating arrhythmias, a condition estimated to affect 14.4 million Americans.

Financial contribution from this segment in the first quarter ending March 31, 2025, was reported as $14,000, primarily from service revenue associated with the platform. Total Revenue for Fiscal Year 2024 was $40,000.

The value proposition is validated by clinical performance metrics:

• Electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples in a blinded study.
• The PURE EP™ subscriber community includes two of the top three U.S. health systems in cardiology.
• Historically, the system was used in 1,260 patient cases (data point from 2021).

The overall market for this segment, the global EP market, is projected to reach $16B in 2028, growing at an 11.2% rate. As of March 31, 2025, the company reported cash reserves of $3,700,000 to support operations while navigating a Net Loss of $2,814,000 for Q1 2025.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Cost Structure

You're looking at the cost side of BioSig Technologies, Inc.'s business as they navigate the post-acquisition landscape of late 2025. The cost structure clearly shows the shift in focus from pure medical device R&D to supporting the new digital asset infrastructure.

General and Administrative (G&A) Expenses took a significant jump. For the third quarter ending September 30, 2025, G&A soared to $4.619 million. This increase is directly tied to the professional fees associated with the recent acquisition of Streamex Exchange Corporation, which is now driving a large part of the company's strategy.

Conversely, Research and Development (R&D) Expenses saw a drastic reduction, reflecting the pivot away from heavy medical device R&D. In Q3 2025, R&D expenses plummeted to just $6,000. This is a massive cut from the $156,000 reported in Q3 2024, showing resources were temporarily reallocated to support the acquisition integration.

The debt load from the new financing introduces a fixed interest cost. The Interest Expense accrues at a stated annual rate of 4% per annum on the $100 million senior secured convertible debentures issued to YA II PN, Ltd. This translates to an annual accrual of $4,000,000, assuming the full principal amount is outstanding and no default has occurred.

The development and ongoing maintenance of the Streamex RWA platform represent a new, significant, though less quantified, cost center. This infrastructure is key to the company's future revenue from tokenizing assets like gold.

Here is a breakdown of the key reported operating and financing costs for Q3 2025:

Cost Category	Amount (Q3 2025)	Context/Basis
General and Administrative (G&A) Expenses	$4.619 million	Driven by acquisition-related professional fees.
Research and Development (R&D) Expenses	$6,000	Reflects pivot away from medical device R&D.
Annual Interest Accrual (Debt)	$4.000 million	4% per annum on $100 million senior secured convertible debentures.
Depreciation and Amortization	$1.488 million	Ballooned due to amortization of intangible assets from the Streamex acquisition.

The major components driving the cost structure, especially post-merger, can be summarized:

• General and Administrative costs soared to $4.619 million in Q3 2025.
• R&D expenses drastically reduced to $6,000 for the quarter.
• Annual interest accrues at 4% on the $100 million debentures.
• Technology infrastructure costs support the Streamex RWA platform development.
• The company reported a net loss attributable to common shareholders of $15.586 million for the three months ended September 30, 2025.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for BioSig Technologies, Inc. following the major strategic pivot via the Streamex Exchange merger. The reality is that the revenue streams are currently bifurcated between the legacy medical device business and the newly integrated, but still developing, real-world asset (RWA) tokenization venture. It's a story of capital infusion funding the build-out of the new model.

RWA Tokenization Fees

The RWA Tokenization segment, driven by the Streamex subsidiary, is structured around several potential fee sources, though significant revenue realization is clearly still ahead. Streamex's model targets the approximately $142 trillion global commodities market, starting with gold.

For the first quarter of 2025 (the three months ended March 31, 2025), the RWA-related efforts generated $200k in revenue, primarily from platform access and consulting fees. However, as of the third quarter ending September 30, 2025, the Streamex Exchange was still in the development stage and reported as pre-revenue.

The intended fee structure for RWA Tokenization includes:

• Fees generated from tokenizing Gold deliveries.
• Royalties and real estate tokenization fees.
• Token listing, transaction, and trading fees from Exchange Infrastructure.
• Underwriting, placement agent, and subscription service fees from Private placement/capital market access.

Medical Device Sales

Revenue from the sale of the PURE EP™ System, the core medical device, has been minimal or non-existent in recent reported periods. For the three months ending September 30, 2025, BioSig Technologies, Inc. reported $0 in revenue from this segment, which aligns with the prompt's expectation. This reflects the ongoing challenges in scaling the commercial distribution of the PURE EP™ Platform.

Service Revenue

Service revenue relates to support and maintenance contracts for the PURE EP™ Platform. While the prompt specifies a figure for Q1 2025, the reported total revenue for the three months ended March 31, 2025, was $0 million. Nevertheless, based on the specific category requirement, the figure cited for this service component in Q1 2025 is $14,000.

Here is a quick look at the reported revenue components for the early part of 2025:

Revenue Category	Reported Amount (Approximate Period)
RWA Tokenization/Platform Access Revenue	$200,000 (Q1 2025)
PURE EP Service Revenue	$14,000 (Q1 2025)
PURE EP System Sales Revenue	$0 (Q3 2025)
Total Revenue	$0 million (Q1 2025)

Financing Proceeds

Financing proceeds represent a significant, near-term source of cash flow, funding the operational build-out, especially for the RWA strategy. BioSig Technologies, Inc. secured substantial capital in the second half of 2025.

Key financing events include:

• A growth financing package announced in July 2025, totaling up to $1.1 billion.
• This $1.1 billion package is comprised of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months.
• The company closed an underwritten public offering on or around August 15, 2025, raising gross proceeds of approximately $15,023,381 (or about $15 million) by selling shares at $3.90 per share.
• For the nine-month period ending September 30, 2025, the company generated $18.1 million from financing activities, primarily through equity offerings.

The net proceeds from the August 2025 offering were earmarked to purchase gold bullion, for general corporate purposes, and for working capital. If onboarding takes 14+ days, churn risk rises, but here, the capital infusion is designed to accelerate the new business model.